Benign prostatic hyperplasia in elderly men What are the special issues in treatment?

Postgraduate Medicine

Volumn 101, Issue 5, 1997, Pages 141-162

  Guthrie, Robert ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; FINASTERIDE;

DISEASE ASSOCIATION; GENERAL PRACTITIONER; HUMAN; IMPOTENCE; MALE; PREOPERATIVE EVALUATION; PROSTATE HYPERTROPHY; RETROGRADE EJACULATION; REVIEW; SURGICAL RISK; TRANSURETHRAL RESECTION;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; PROSTATECTOMY; PROSTATIC HYPERPLASIA;

EID: 0030986206     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.1997.05.243     Document Type: Article

References (21)

1. Guess HA. Benign prostatic hyperplasia: antecedents and natural history. EpidemiolRev 1992;14:131-53
2. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol 1995;168(Suppl 29): 7-12
3. Altwein JE. Individualization of treatment in benign prostatic hyperplasia. Eur Urol 1996;29(Suppl l):2-6
4. Tsang KK, Garraway WM. Prostatism and the burden of benign prostatic hyperplasia on elderly men. Age Ageing 1994; 23(5):360-4
5. Cadieux RJ. Geriatric psychopharmacology: a primary care challenge. Postgrad Med 1993;93(4):281-301
6. McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign prostatic hyperplasia: diagnosis and treatment. Quick reference guide for clinicians. Rockville, Md: Agency for Health Care Policy and Research, Public Health Service, Dept of Health and Human Services, 1994 Feb; AHCPR publication No. 94-0583
7. Cockett AT, Aso Y, Denis L, et al. Recommendations of the International Consensus Committee. In: Cockett AT, Khoury S, Aso Y, et al. Proceedings of the 3rd International Consultation on Benign Prostatic Hyperplasia (BPH). Jersey: Scientific Communication International Ltd, 1996:625-40
8. Measurement Committee of the American Urological Association. American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992; 148(5):1549-57
9. Mebust WK, Holtgrewe HL, Cockett AT, et al. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. ]Uroll989;141(2):243-7
10. Wyatt MG, Stower MJ, Smith PJ, et al. Prostatectomy in the over 80-year-old. BrJUroll989;64(4):417-9
11. Landsberg L. Unique problems in the treatment of the older hypertensive male. Introduction: increased sympathetic nervous system activity in the elderly. Br J Clin Pract 1994;74(Symp Suppl):l-3
12. Pool JL. Role of the sympathetic nervous system in hypertension and benign prostatic hyperplasia. Br J Clin Pract 1994; 74(Symp Suppl):13-7
13. Wilde MI, Fitton A, Sorkin EM. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs Aging 1993;3(3): 258-77
14. Kaplan SA. Doxazosin in the older male: efficacy in treating benign prostatic hyperplasia. EurUrol 1996;29(Suppl 1): 17-23
15. Vincent J, Meredith PA, Elliott HL, et al. The pharmacokinetics of doxazosin in elderly normotensives. Br J Clin Pharmacol 1986;21(5):521-4
16. Kaplan SA, Soldo KA, Olsson CA. Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety. Eur Urol 1995; 28(3):223-8
17. Langdon CG, Packard RS. Doxazosin in hypertension: results of a general practice study in 4809 patients. Br J Clin Pract 1994;48(6):293-8
18. Jardin A, Kirby R, Christensen MM, et al. Doxazosin is equally well tolerated by older and younger normotensive men. J Urol 1995;153(Suppl):273A, abstr 179
19. The Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993; 22(4):291-9
20. McConnell J, Akakura K, Akaza H, et al. Hormonal treatment of benign prostatic hyperplasia. In: Cockett et al, Proceedings of the 3rd International Consultation on Benign Prostatic Hyperplasia (BPH),' pp 497-526
21. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996;335(8):533-9